X

Halozyme Therapeutics, Inc (HALO) U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma

Halozyme Therapeutics, Inc (NASDAQ: HALO) FY 2026 Other Release

Newsdesk: